Name: The Common Cold: What Actually Prevents and Shortens It (and the Long List That Doesn't)
Creator: Realised
Published: 2026-06-01

Summary

A short list of things genuinely helps with the common cold and most of the cold/immune-boost market does not, and the dividing line is not "natural versus pharma" but corrects a specific deficit or blocks transmission (works) versus generically boosts a healthy immune system (doesn't): regular vitamin C modestly shortens duration but does NOT prevent colds and does little when started at onset, zinc lozenges taken early at adequate dose and in the right form genuinely shorten colds though the magnitude is contested, correcting vitamin D deficiency (not topping up replete people) cuts respirat

Why Strong

Strong Evidence because the entry's load-bearing claims rest on the highest-grade evidence available for this question: large Cochrane meta-analyses (the vitamin C prevention null and modest duration effect), an individual-participant-data meta-analysis (vitamin D deficiency-correction), a viral-challenge experiment (sleep), and Cochrane physical-interventions evidence (handwashing). These are not "a few suggestive studies"; they are the primary-endpoint, gold-standard syntheses for the field.

NOT Foundational because the entry carries genuine clinical and commercial judgement and a live, two-sided controversy (the zinc magnitude dispute), not a single undisputed axiom.

NOT Moderate for the headline, because the spine — vitamin C does not prevent, deficiency-correction and behavioural levers do, the at-onset reflex does not — is Cochrane- and IPD-backed and robust. Only specific interventions sit lower, and the entry marks them rather than inheriting their uncertainty.

The per-intervention split (read this, not just the headline):
• Vitamin C prevention null + regular-use duration effect + athlete subgroup: Strong (large Cochrane meta-analysis).
• Zinc lozenges: Strong-to-Moderate with a live dispute — real but contested in magnitude (Hemilä reanalyses versus cautious Cochrane 2024). Present both.
• Vitamin D deficiency-correction: Strong (IPD meta-analysis); the deficiency-only and daily-not-bolus nuances are load-bearing.
• Sleep: Strong-to-Moderate (viral-challenge design; small n, wide CIs).
• Hand hygiene: Strong (Cochrane); the co-located mask finding is contested and out of scope.
• Echinacea / elderberry: Emerging-to-Experimental — heterogeneity and manufacturer-linked bias preclude a higher tier.

Practical takeaway

The framing to hold: prevention is mostly a transmission-and-recovery problem. The durable wins are sleep and handwashing plus correcting any genuine deficiency. The at-onset supplement reflex is the part the evidence does not support — with one fussy exception.

Prevent first (the highest-yield, lowest-cost levers).
• Sleep. Protect adequate sleep, especially when you are likely to be exposed. Under-sleeping multiplies your odds of getting infected after exposure several-fold. This is the prevention lever with the strongest design and nothing to sell.
• Handwashing. Wash hands regularly and properly. It interrupts transmission, which is the cheapest point of intervention. It outperforms most of the supplement shelf.

Correct genuine deficiencies (not blanket supplementation).
• Vitamin D if you are actually deficient — the benefit is concentrated in the profoundly deficient and absent in replete people. Use daily or weekly dosing; large single bolus doses did not work. This is correction, not a generic "immune boost." Dosing specifics are owned by vitamin_d3_high_dose_supplementation.
• Regular vitamin C (≥0.2 g/day) is a modest, optional duration-shortener — but it will not prevent colds, and it is most worth considering for people under extreme physical stress (endurance athletes, extreme cold exertion), not the general desk-bound population.

The one at-onset exception — zinc lozenges, done right.
• If you use zinc lozenges, start them early (within the first day of symptoms), at an adequate total daily elemental dose (the supportive trials used ≥75 mg/day, with no extra benefit above ~100 mg/day), in lozenge form so the zinc is released locally in the throat.
• Be honest about the uncertainty: the magnitude is contested (cautious Cochrane versus more bullish reanalyses), and lozenges commonly cause nausea and a bad metallic taste. Never use intranasal zinc — it carries a risk of loss of smell. Zinc/copper-balance detail is owned by zinc_supplementation_and_copper_balance.

What to skip (the marketing, not the medicine).
• The at-onset vitamin C megadose. It does little.
• High-dose multi-ingredient "immune" stacks, echinacea, and most elderberry products. The evidence is weak, heterogeneous, and often manufacturer-funded.
• "Vitamin D for everyone to prevent colds" if you are already replete. No deficit, no benefit.

Evidence detail

Why This Entry Exists

The instinct when you feel a cold coming on is to reach for vitamin C, and that instinct is the single most popular thing the evidence does NOT support. Taken at onset, vitamin C does little. Taken regularly it shaves a small slice off duration but does not stop you catching colds at all. That gap — between what people do and what works — is the reason this entry exists, and it generalises: the cold and "immune support" market is built largely on the at-onset reflex and on a vague promise to "boost immunity," and the strongest-sounding observational claims behind it are riddled with healthy-user confounding, because the people who take supplements also sleep, train and eat better than the people who don't.

But the honest read is not blanket dismissal. A few interventions genuinely work, each by a specific mechanism and only under specific conditions. Zinc lozenges, started early and dosed adequately, really do shorten colds. Correcting a genuine vitamin D deficiency really does cut respiratory infections. Adequate sleep before exposure really does change your odds of getting infected, and handwashing really does interrupt transmission. The point of the entry is to hold both truths at once and to draw the line in the right place — not natural versus pharma, but narrow correction under a stated condition (works) versus generic boost of an already-healthy system (doesn't).

What bad advice this protects against, in all directions:
• "Take vitamin C when you feel a cold coming on" → the at-onset megadose does little; the small benefit is from regular prophylactic use, and even that does not prevent colds, only modestly shortens them.
• "Vitamin C prevents colds" → it does not, in the general population (pooled RR 0.97). The prevention claim is a clean, robust null.
• "Zinc is useless / zinc is a cure" → both are wrong. Early, adequate-dose lozenges genuinely shorten colds; the magnitude is contested between a cautious Cochrane review and the more bullish reanalyses, and most consumers take zinc in the wrong form, dose or timing.
• "Vitamin D prevents colds, everyone should take it" → only correcting deficiency helps, and only with daily/weekly dosing; topping up replete people does nothing, and large single bolus doses do nothing.
• "Immune-boosting stacks, echinacea and elderberry work" → these rest on heterogeneous, high-bias, often manufacturer-linked trials; the evidence is weak.
• "There's nothing you can do but wait it out" → false in the other direction: sleep and handwashing are real, cheap, well-supported prevention levers.

This entry owns the canonical consensus-gaps of cold prevention and treatment. It defers general immune function to immune_function_cross_pillar_optimisation, the zinc/copper detail to zinc_supplementation_and_copper_balance, and vitamin D dosing to vitamin_d3_high_dose_supplementation. It states those boundaries and routes there rather than re-arguing them.

Evidence

Organised by intervention, with the tier signal inline. The headline is Strong, but the interventions split — read the tiers, not just the thesis.

Vitamin C — prevention fails, regular use modestly shortens, at-onset does little (Strong Evidence for the pattern).

1. Regular vitamin C does NOT prevent colds in the general population. Pooled across 29 trials and 11,306 participants, regular supplementation (≥0.2 g/day) gave a risk ratio of 0.97 (95% CI 0.94–1.00) for cold incidence — a robust null with a tight confidence interval touching 1.0. The popular prevention claim is a genuine consensus gap: it fails. (Hemilä H, Chalker E. Cochrane Database Syst Rev 2013;(1):CD000980. Strong Evidence — large meta-analysis, tight CI, robust null. The author is an academic vitamin-C researcher arguably sympathetic to a positive effect, yet reports the null honestly — which strengthens it.)

2. Regular (prophylactic) vitamin C modestly shortens cold DURATION, but at-onset therapeutic use does not. Regular use shortened duration by about 8% in adults and 13% in children at ≥0.2 g/day. But vitamin C started after symptom onset showed no consistent effect on duration or severity across 7 comparisons and 3,249 episodes. This is the decision-relevant asymmetry: the daily habit slightly helps; the at-onset megadose — the thing most people actually do — does little. (Hemilä H, Chalker E, Cochrane Database Syst Rev 2013;(1):CD000980, duration subgroups. Strong for the regular-use duration effect; the therapeutic null is the more decision-relevant finding. Effect small enough that dose-response artefacts can't be fully excluded, but direction is consistent.)

3. Vitamin C roughly halves cold risk under EXTREME physical stress only. In 5 trials of marathon runners, skiers and soldiers (598 participants), regular vitamin C cut cold incidence with RR 0.48 (95% CI 0.35–0.64). This bounds who actually benefits from prevention: endurance athletes and people under extreme cold-exertion stress, not desk workers — for whom the general-population RR is 0.97. A textbook "true but narrow" finding; do not generalise it. (Hemilä H, Chalker E, Cochrane Database Syst Rev 2013;(1):CD000980, extreme-exertion subgroup. Strong within its narrow population; small n, population-specific.)

Zinc lozenges — a genuine at-onset exception, but fussy and contested (Strong-to-Moderate, with a live dispute).

4. Zinc lozenges started early, at adequate dose and in lozenge form, shorten cold duration. Pooled across 7 trials and 575 participants, lozenges delivering ≥75 mg/day elemental zinc shortened colds by about 33% (95% CI −21% to −45%); zinc acetate (−40%) versus gluconate (−28%) did not differ significantly, and there was no extra benefit above roughly 100 mg/day. The catches are form, dose and early timing — the three things most consumers get wrong. (Hemilä H, JRSM Open 2017;8(5):2054270417694291. Strong-to-Moderate — a real effect, but the restrictive inclusion criteria, >75 mg/day and lozenge-only, limit generalisability and the effect shrinks under broader criteria. The author is a vocal zinc-lozenge advocate — weigh against the cautious Cochrane review below.)

5. The 2024 Cochrane zinc review is far more cautious, and the magnitude is genuinely contested. Cochrane concluded the evidence is "insufficient to provide firm conclusions or recommend zinc" for prevention or treatment, while noting adult trials suggest symptoms around 2–3 days shorter. Hemilä and colleagues published a formal critique alleging trial inclusion/exclusion and statistical errors, arguing lozenges shorten colds by around 37%. The existence of this live methodological dispute is itself the honest signal — present both, not a single confident number. (Nault D et al., Cochrane Database Syst Rev 2024;CD014914.pub2, cautious; critique: Hemilä H et al., Front Med 2024;11:1470004. Moderate. A clean two-sided cui-bono: institutional conservatism versus a researcher invested in the positive result. Truth is "real but smaller and fussier than supplement marketing claims.")

Vitamin D — deficiency correction only, and dosing matters (Strong Evidence).

6. Correcting vitamin D DEFICIENCY reduces respiratory infections; topping up replete people does not. In an individual-participant-data meta-analysis of 25 trials and 10,933 participants, supplementation gave an overall adjusted odds ratio of 0.88 (95% CI 0.81–0.96, NNT 33) for acute respiratory infection — but the effect was concentrated in the profoundly deficient (<25 nmol/L: aOR 0.58, 0.40–0.82, NNT 8) and absent at ≥25 nmol/L (aOR 0.89, 0.77–1.04). Daily or weekly dosing worked (aOR 0.81); large bolus doses did NOT (aOR 0.97). "Vitamin D prevents colds" for replete people is exactly the marketing error this finding punctures. (Martineau AR et al., BMJ 2017;356:i6583. Strong Evidence — individual-participant-data meta-analysis, the gold standard; deficiency-vs-replete and daily-vs-bolus splits are load-bearing. The lead author has vitamin-D consulting ties, but the IPD method and pre-specified subgroups mitigate this, and the "only if deficient" result cuts AGAINST blanket supplementation. Defer dosing, and any more recent synthesis, to vitamin_d3_high_dose_supplementation; the two entries agree the benefit is concentrated in deficiency-correction.)

Sleep — under-rated relative to the supplement aisle (Strong-to-Moderate, causal-grade design).

7. Short sleep before exposure sharply raises infection risk in a viral-challenge study. With sleep measured objectively by actigraphy and participants then inoculated with standardised rhinovirus under quarantine (n=164), people sleeping under 5 hours had odds of developing a clinical cold of 4.50 (95% CI 1.08–18.69) versus those sleeping more than 7 hours, and 5–6 hour sleepers 4.24 (1.08–16.71). This is a causal-grade exposure with no product to sell — partly why it is culturally under-rated next to supplements. (Prather AA, Janicki-Deverts D, Hall MH, Cohen S. Sleep 2015;38(9):1353–1359. Strong-to-Moderate — experimental viral-challenge design, but small n and wide CIs; direction strong and mechanistically coherent. NIH-funded, no supplement-industry interest.)

Hand hygiene — cheap behavioural prevention that beats most of the shelf (Strong Evidence).

8. Hand hygiene reduces respiratory-virus spread. The Cochrane physical-interventions review found consistent support for hand hygiene as a transmission-reducing lever. The same review found insufficient evidence that medical/surgical masks reduce respiratory illness in community settings, a finding that is widely misread and which Cochrane itself issued a clarifying statement on — so cite it only for what it covers. Hand-hygiene benefit is the safe, supported claim; the mask portion attracted heavy criticism and an editorial clarification, and should not be stretched into "masks don't work" outside this entry's scope. (Jefferson T et al., Cochrane Database Syst Rev 2023;(1):CD006207.pub6. Strong for hand-hygiene direction; the mask finding is contested and outside scope.)

Echinacea and elderberry — sounds plausible, doesn't deliver (Emerging-to-Experimental).

9. Echinacea and elderberry evidence is too heterogeneous and bias-prone to support. For echinacea, 24 trials covering 4,631 participants used chemically diverse extracts, so Cochrane made an a priori decision NOT to pool them; the signal was weak and inconsistent, with 8 of 24 trials at high risk of bias. For elderberry, a handful of small RCTs may shorten duration but the evidence is uncertain and several of the positive trials are manufacturer-linked. These are the "sounds plausible, doesn't deliver" category. (Karsch-Völk M et al., Cochrane Database Syst Rev 2014;(2):CD000530.pub3, echinacea; Wieland LS et al., BMC Complement Med Ther 2021;21:112, elderberry. Emerging-to-Experimental — heterogeneity and bias preclude a higher tier. Several elderberry RCTs were funded by extract manufacturers — classic cui-bono toward a positive result; weight down accordingly.)

Mechanism

Why "corrects a deficit / blocks transmission" works and "generic boost" doesn't. A healthy immune system is not a dial you can turn up. The interventions that work do so by restoring something that was missing or by stopping the virus reaching you, not by amplifying a system that is already operating normally. Vitamin D illustrates this most cleanly: it is a substrate for antimicrobial peptide production and immune signalling, so restoring a deficient level restores a capacity that was impaired — but adding more to someone already replete adds nothing, because the capacity was not the limiting factor. The same logic explains why "boosting" a normal immune system with megadose stacks does little: there is no deficit to correct.

Why regular vitamin C shortens but at-onset does little. Vitamin C is concentrated in immune cells and consumed during the oxidative stress of infection. Maintaining tissue saturation before and during exposure plausibly supports the cells that are already working, which fits the small regular-use duration effect. Loading it in after symptoms have started cannot retroactively change the early course, which fits the at-onset null. The asymmetry is mechanistically coherent, not a statistical fluke.

Why zinc lozenges are timing-, dose- and form-fussy. The proposed mechanism is local: zinc ions released in the throat and nasopharynx interfere with rhinovirus replication and binding at the site of infection. That mechanism only operates if free zinc ions are actually released (form matters — some formulations bind the zinc so little is available), at sufficient concentration (dose matters), and while viral replication is still in its early exponential phase (early timing matters). Miss any of the three and the local mechanism never engages, which is why most consumers get no benefit and why the effect size is so sensitive to trial inclusion criteria.

Why sleep and handwashing are upstream of all of it. Short sleep is associated with impaired immune signalling and raised susceptibility on exposure, so adequate sleep acts before the infection establishes. Handwashing acts even further upstream, on transmission itself — the cheapest possible point of intervention, because the infection that never reaches you needs no immune response at all. Both are prevention by removing the exposure or strengthening the host before contact, which is precisely the "specific condition" framing the supplement reflex lacks.

Risks And Contraindications

• Zinc magnitude over-claim is the central hazard. The headline −33% to −40% numbers come from restrictive reanalyses (≥75 mg/day, lozenge-only, early-start) by a researcher invested in the positive result; the 2024 Cochrane review is markedly more cautious. Do NOT present a single confident percentage — present the dispute.
• Zinc adverse effects. Lozenges commonly cause nausea and a bad taste. Intranasal zinc carries a risk of anosmia (loss of smell) and should never be recommended. Sustained high-dose zinc also depletes copper over time — a reason not to run high zinc doses beyond the brief duration of a cold (see zinc_supplementation_and_copper_balance).
• Vitamin D over-generalisation. The benefit is deficiency-correction only and vanishes with bolus dosing. Presenting it as "vitamin D prevents colds" for replete people is exactly the marketing error this entry exists to puncture.
• Mask finding is widely misread. The Jefferson 2023 review is cited here ONLY for hand hygiene (supported); its community-mask portion attracted heavy criticism and a Cochrane clarifying statement, and must not bleed into a "masks don't work" claim outside scope.
• Red-flag boundary. This entry is about the ordinary self-limiting common cold. Symptoms that are severe, persistent beyond the usual course, or accompanied by high fever, breathing difficulty, or chest pain are not a "cold" question and warrant medical assessment.

Controversy

Nature: a small set of genuinely-effective interventions (regular vitamin C for duration, early zinc lozenges, deficiency-correction vitamin D, sleep, handwashing) entangled with a large, profitable market of unsupported "immune boosters," with error at both poles — over-claiming on one side, and a quieter under-claiming on the other where a real-but-fussy zinc effect gets dismissed.

Position A — "A short list genuinely works." The grounded, mechanism-specific take.
• Best evidence: real where it stays narrow. Regular vitamin C shortens duration ~8% in adults; early adequate-dose zinc lozenges shorten colds; correcting vitamin D deficiency cuts respiratory infections; short sleep multiplies infection odds in a viral-challenge design; handwashing interrupts transmission. Each holds only under its stated condition.
• Where it goes wrong if overstated: it tips into "immune boosting" if you forget the conditions — generalising the zinc number, the athlete-only vitamin C benefit, or the deficiency-only vitamin D benefit to everyone.

Position B — "Most of the cold/immune market is unsupported." The skeptical take.
• Best evidence: correct on the big-ticket claims — vitamin C does not prevent colds (RR 0.97) and does little at onset; high-dose stacks, echinacea and most elderberry rest on heterogeneous, high-bias, often manufacturer-linked trials; observational "this supplement boosts immunity" claims are contaminated by healthy-user confounding.
• Where it goes wrong if overstated: it can slide into "nothing works," dismissing the real-but-fussy zinc effect and the genuine deficiency-correction and behavioural levers. The cautious-Cochrane-versus-Hemilä zinc dispute lives exactly here.

The funding/bias dimension — cui bono, both ways. Toward over-claiming: the supplement and "immune support" market profits from the at-onset reflex (vitamin C megadose products, multi-ingredient stacks), several positive echinacea/elderberry trials carry manufacturer funding, and individual academic advocates have reputational stakes in positive findings. Toward under-claiming: Cochrane and public-health bodies are structurally cautious and arguably under-credit a real zinc effect — which is what prompted the formal Frontiers critique.

Realised Position: Both positions are simultaneously true and that is the entire entry. The dividing line is not "natural versus pharma" but corrects a deficit / blocks transmission under a specific condition (works) versus generic boost of an already-healthy system (doesn't). We frame the cold as mostly a transmission-and-recovery problem: the durable wins are sleep and handwashing for prevention plus deficiency correction. The at-onset supplement reflex — vitamin C when you feel a cold coming on — is precisely the thing the evidence does NOT support. Zinc lozenges are the one at-onset exception, and even that is dose-, form- and timing-fussy enough that most people take it wrong. The cleanest tell of an honest finding is the levers with NOTHING to sell — sleep and handwashing — which is exactly why they are culturally under-rated next to the supplement aisle.

Cross-Pillar Connections

This is a genuinely cross-pillar topic — prevention spans sleep, behaviour, and nutrition, and the bias analysis spans method.
• Cross-pillar (immune_function_cross_pillar_optimisation): the general immune-function umbrella this entry feeds; this entry owns the cold-specific consensus gaps and defers broad immune optimisation there.
• Supplements (zinc_supplementation_and_copper_balance): owns zinc form, dosing and the copper-depletion tradeoff; this entry holds only the cold-treatment use case and the intranasal-anosmia warning.
• Supplements (vitamin_d3_high_dose_supplementation): owns vitamin D dosing; this entry holds only the deficiency-correction-cuts-respiratory-infections finding.
• Supplements (universal_nearuniversal_supplementation): the broader question of which supplements are worth taking universally — relevant to the "immune stack" overclaim this entry punctures.
• Foundations (healthy_user_bias): the silent contaminant under observational "immune boost" claims; supplement-takers differ systematically from non-takers.
• Foundations (publication_bias_and_evidence_distortion): why the positive echinacea/elderberry and small zinc trials are over-represented in print.

What would change our mind

Falsifiability: explicit upgrade/downgrade criteria from source

• We'd downgrade zinc from "genuine exception" toward "weak" if a large, pre-registered, adequately-powered RCT of zinc acetate lozenges — standardised dose, form and early-start — resolved the Cochrane-2024-versus-Hemilä dispute near the null.
• We'd overturn the "deficiency-correction only" vitamin D framing if an RCT showed supplementation prevents colds in genuinely replete individuals (≥50 nmol/L). The current individual-participant-data evidence argues strongly it won't.
• We'd move echinacea or elderberry from Emerging-to-Experimental toward Moderate if a high-quality, manufacturer-INDEPENDENT RCT showed a clinically meaningful, replicated duration effect.
• We'd harden the sleep lever from Strong-to-Moderate to firm Strong if a viral-challenge replication of Prather confirmed the short-sleep odds ratio with tighter confidence intervals.
• We'd weaken even the modest vitamin C duration claim if the ~8% effect proved to be a publication-bias artefact — for example, if it disappeared under trial-sequential analysis.
• What would NOT move us: the vitamin C prevention null (RR 0.97, tight CI), the deficiency-versus-replete split for vitamin D, or the fact that the at-onset megadose reflex is unsupported. Across all of it, independent (non-seller) funding is the decisive variable.

Industry bias note

Structural incentives the evidence base may reflect

Cui bono runs both ways here, and the entry says so.
• Toward over-claiming. The supplement and "immune support" market profits from the at-onset reflex the evidence does not support — vitamin C megadose products, multi-ingredient "immune" stacks, and elderberry brands whose own RCTs are manufacturer-linked. Several positive echinacea and elderberry trials carry extract-manufacturer funding (a classic cui-bono toward a positive result). And individual academic advocates have reputational stakes in positive findings — a known dynamic in the vitamin-C and zinc literature, and the vitamin-D meta-analysis lead author has consulting ties in that space (though the IPD method and pre-specified subgroups mitigate it, and his key finding cuts against blanket supplementation).
• Toward under-claiming / institutional conservatism. Cochrane's 2024 zinc review and public-health bodies are structurally cautious and arguably under-credit a real-but-fussy zinc effect — which is precisely why a formal critique was published. Institutional conservatism is a bias too, just in the opposite direction.
• The clean signal. The supported levers with NOTHING to sell — sleep (NIH-funded viral-challenge work) and handwashing (Cochrane) — are the cleanest tells of honest findings, and they are exactly the ones culturally under-rated relative to the supplement aisle.
• The silent contaminant. Healthy-user confounding sits under nearly every observational "this supplement boosts immunity" claim: supplement-takers also sleep, train and eat better, so cohort associations inflate effects that the RCTs then shrink (see healthy_user_bias). Publication bias compounds it, favouring the positive trials that reach print (see publication_bias_and_evidence_distortion).

The Common Cold: What Actually Prevents and Shortens It (and the Long List That Doesn't)